Friday, September 29, 2023

561.316.3330

Biotechnology News Magazine

Christian Seufert Appointed President of Capsules and Health Ingredients Division

Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Christian Seufert appointment as president of Capsules and Health Ingredients Division will be effective from 1 July 2022. Christian will succeed Claude Dartiguelongue as a member of the Lonza Group Executive Committee.

Christian Seufert joins Lonza Group from BASF, where he has worked for the last 20 years. Most recently, he held the role of Senior Vice President for the Global Business Unit Pharma Solutions and represented the Nutrition & Health division in North and South America since 2018. In this role, Christian was responsible for driving organic growth with a focus on biologics and new digital business models. With his global team he delivered new product line strategies for selected APIs and pharmaceutical excipients, improved operational excellence, and managed business continuity through the COVID-19 pandemic.

Albert M. Baehny, Chairman, Lonza, commented: “We extend a warm welcome to Christian as he joins the Lonza Group Executive Committee. Christian will lead a thriving Division which delivers strong cash generation and shows high long-term potential. His knowledge and understanding of our business will help us to achieve further improvements in operational excellence while continuing our growth journey.”

Pierre-Alain Ruffieux, CEO, Lonza, added: “Christian is uniquely placed to lead our CHI business, with a wealth of experience and expertise in both our operations as well as the industry in which we operate. Christian joins our leadership team as we continue to consolidate our leading market position and maintain our focus on driving accelerated growth and long-term success.”

Prior to his most recent role in BASF, Christian held multiple roles with increasing levels of responsibility in BASF Group. Other roles have included Vice President of the global Aroma Ingredients business (2015 – 2018) and Vice President for the European Business Management Home Care, Industrial and Institutional Cleaning (2012 – 2014).

Christian holds a graduate degree in business administration and economics from the University of Hohenheim as well as Executive and post-graduate qualifications from INSEAD and IMD Business School (Lausanne, Switzerland). He is relocating from the US to live in Basel with his wife.

Christian Seufert will succeed Claude Dartiguelongue, who has been the President of the Capsules and Health Ingredients Division since January 2020. Claude has played a critical role in creating a clear organizational structure and performance culture in the CHI Division, as well as maintaining a focus on quality and speed. She has set the strategic direction of the Division, while enhancing the approach to customer-centricity and value creation. As part of her role on the Executive Committee, Claude has also played an instrumental role in strategic projects across the Group.

Claude will retire on 31 July 2022. She is a highly regarded member of the Lonza leadership and she will be greatly missed by her colleagues. The Lonza management would like to thank her for her many valuable contributions, and wish her a well-deserved happy retirement.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine